| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 25, 2017- First and only subcutaneous preventive treatment option reduced HAE attacks by 95 percent (median) in treated patients - Comprehensive support program offered to patients
25 Jul 2017 KING OF PRUSSIA, Pa. — 25 July 2017 Global biotherapeutics leader CSL Behring today announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in...
-
Jul 21, 2017FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks
21 Jul 2017 KING OF PRUSSIA, Pa. — 21 July 2017 Global biotherapeutics leader CSL Behring today announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven...
-
Jul 19, 2017For the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
19 Jul 2017 KING OF PRUSSIA, Pa. — 19 July 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s...
-
Jul 12, 2017Findings presented at the International Society on Thrombosis and Haemostasis Congress 2017 show product’s impact on treatment adherence, consumption and quality of life
12 Jul 2017 BERLIN — 12 July 2017 CSL Behring today presented data finding that prophylaxis treatment with IDELVION® provides consistently high factor IX levels, resulting in low bleeding rates...
-
Jul 11, 2017CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards
11 Jul 2017 SITGES, Spain — 11 July 2017 Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society’s annual meeting the winners of its annual Interlaken...
-
Jul 10, 2017Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017
10 Jul 2017 BERLIN — 10 July 2017 CSL Behring today presented data finding treatment with AFSTYLA® may result in low average product consumption without compromising efficacy in both the...
-
Jul 6, 2017New findings demonstrate CSL Behring’s promise to develop and deliver innovative treatments that improve patients’ lives
06 Jul 2017 MARBURG, Germany. — 06 July 2017 CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the International Society...
-
Jun 23, 2017- HAEGARDA has been shown to reduce HAE attacks by 95 percent (median) in patients with a life-threatening, rare genetic disorder - Use of rescue medication was reduced by greater than 99 percent (1) - Subcutaneous administration builds and maintains steady-state C1-INH levels
23 Jun 2017 KING OF PRUSSIA, Pa. — 23 June 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved HAEGARDA® (C1 Esterase...
-
May 19, 2017Driven by its promise to save lives and protect people’s health, CSL Behring is honoured to be recognized by NORD, a tireless advocate for rare disease patients.
19 May 2017 KING OF PRUSSIA, Pa. — 19 May 2017 CSL Behring received the National Organization for Rare Disorders’ (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for...
-
Apr 19, 2017- AFSTYLA is the first and only single-chain recombinant factor VIII product to treat haemophilia A.
19 Apr 2017 MELBOURNE, Australia — 19 April 2017 AFSTYLA is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A AFSTYLA reduces the number of...